BackCOSCIENS Biopharma Overview

COSCIENS Biopharma Total Current Liabilities

Track COSCIENS Biopharma's total current liabilities ($5.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$5.53M
↓ 44.11% YoYΔ $-4.37M vs prior year quarter

Peer average

Loading

COSCIENS Biopharma Total Current Liabilities History

Loading

COSCIENS Biopharma vs. peers: Total Current Liabilities Comparison

Loading

COSCIENS Biopharma Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

COSCIENS Biopharma (CSCI) FAQ

The latest total current liabilities for CSCI is $5.5M as of June 2025. That compares with $9.9M in the prior-year period — down 44.1% year over year. Investors often review this figure alongside COSCIENS Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CSCI's total current liabilities moved from $9.9M to $5.5M — a 44.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in COSCIENS Biopharma's operating scale or balance-sheet position.

A total current liabilities figure of $5.5M for CSCI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CSCI's total current liabilities ($5.5M), review year-over-year change from $9.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.